Hydroxytyrosol supplementation improves antioxidant and anti-inflammatory status in individuals with overweight and prediabetes: A randomized, double-blind, placebo-controlled parallel trial

IF 7.4 2区医学 Q1 NUTRITION & DIETETICS

Clinical nutrition Pub Date : 2025-07-12 DOI:10.1016/j.clnu.2025.07.006

Ignacio Moratilla-Rivera , Jara Pérez-Jiménez , Sonia Ramos , María Puy Portillo , María Ángeles Martín , Raquel Mateos

{"title":"Hydroxytyrosol supplementation improves antioxidant and anti-inflammatory status in individuals with overweight and prediabetes: A randomized, double-blind, placebo-controlled parallel trial","authors":"Ignacio Moratilla-Rivera , Jara Pérez-Jiménez , Sonia Ramos , María Puy Portillo , María Ángeles Martín , Raquel Mateos","doi":"10.1016/j.clnu.2025.07.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Background & aim</h3><div>Hydroxytyrosol (HT), an olive-derived phenolic compound, possesses well-known antioxidant and anti-inflammatory properties. While its benefits in healthy individuals and as part of extra virgin olive oil are well studied, its preventive role as a dietary supplement in at-risk populations remains less explored. This study investigates the potential of HT supplementation in preventing aging-related diseases in overweight individuals with prediabetes.</div></div><div><h3>Methods</h3><div>A randomized, double-blind, placebo-controlled trial was conducted in adults with overweight and prediabetes (40–70 years). For 16 weeks, volunteers consumed either 15 mg of HT or a placebo daily. The primary outcome were oxidized LDL (oxLDL) levels, while secondary outcomes included biochemical and metabolic parameters, oxidative stress and inflammation biomarkers, and lifestyle assessments. Compliance was verified through urinary HT-3′-sulphate levels.</div></div><div><h3>Results</h3><div>A total of 52 participants were recruited and randomized, with 49 completing the study. They were then allocated to either the HT-treated group (n = 24) or the placebo group (n = 25). Compliance was confirmed, as the HT-supplemented group showed increased urinary HT-3′-sulphate levels, whereas the placebo group exhibited a significant decrease (<em>p</em> = 0.039). Compared with placebo, HT supplementation significantly reduced oxLDL levels (<em>p</em> = 0.045), protein carbonyls (<em>p</em> = 0.031), and 8-OHdG (<em>p</em> < 0.01). Additionally, it prevented a decline in total antioxidant status (<em>p</em> < 0.01) and GPx activity (<em>p</em> < 0.01). An anti-inflammatory effect was also observed, with reduced IL-6 levels (<em>p</em> = 0.05). No significant changes were found in lipid profile, anthropometric parameters, or lifestyle factors such as sleep, mental well-being, or physical capacity. No adverse events were observed throughout the intervention.</div></div><div><h3>Conclusion</h3><div>Chronic supplementation with 15 mg/day of HT for 16 weeks significantly improved antioxidant and anti-inflammatory status in individuals with overweight and prediabetes, suggesting a potential preventive role against aging-related diseases.</div></div><div><h3>Registration number of Clinical Trial</h3><div>NCT 06295913 (<span><span>https://clinicaltrials.gov/study/NCT06295913?intr=Hydroxytyrosol&amp;page=2&amp;rank=1</span><svg><path></path></svg></span>).</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"52 ","pages":"Pages 17-26"},"PeriodicalIF":7.4000,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical nutrition","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0261561425001827","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background & aim

Hydroxytyrosol (HT), an olive-derived phenolic compound, possesses well-known antioxidant and anti-inflammatory properties. While its benefits in healthy individuals and as part of extra virgin olive oil are well studied, its preventive role as a dietary supplement in at-risk populations remains less explored. This study investigates the potential of HT supplementation in preventing aging-related diseases in overweight individuals with prediabetes.

Methods

A randomized, double-blind, placebo-controlled trial was conducted in adults with overweight and prediabetes (40–70 years). For 16 weeks, volunteers consumed either 15 mg of HT or a placebo daily. The primary outcome were oxidized LDL (oxLDL) levels, while secondary outcomes included biochemical and metabolic parameters, oxidative stress and inflammation biomarkers, and lifestyle assessments. Compliance was verified through urinary HT-3′-sulphate levels.

Results

A total of 52 participants were recruited and randomized, with 49 completing the study. They were then allocated to either the HT-treated group (n = 24) or the placebo group (n = 25). Compliance was confirmed, as the HT-supplemented group showed increased urinary HT-3′-sulphate levels, whereas the placebo group exhibited a significant decrease (p = 0.039). Compared with placebo, HT supplementation significantly reduced oxLDL levels (p = 0.045), protein carbonyls (p = 0.031), and 8-OHdG (p < 0.01). Additionally, it prevented a decline in total antioxidant status (p < 0.01) and GPx activity (p < 0.01). An anti-inflammatory effect was also observed, with reduced IL-6 levels (p = 0.05). No significant changes were found in lipid profile, anthropometric parameters, or lifestyle factors such as sleep, mental well-being, or physical capacity. No adverse events were observed throughout the intervention.

Conclusion

Chronic supplementation with 15 mg/day of HT for 16 weeks significantly improved antioxidant and anti-inflammatory status in individuals with overweight and prediabetes, suggesting a potential preventive role against aging-related diseases.

Registration number of Clinical Trial

NCT 06295913 (https://clinicaltrials.gov/study/NCT06295913?intr=Hydroxytyrosol&page=2&rank=1).

查看原文本刊更多论文

补充羟基酪醇可改善超重和糖尿病前期患者的抗氧化和抗炎状态：一项随机、双盲、安慰剂对照的平行试验

背景,羟基酪醇（HT）是一种橄榄衍生的酚类化合物，具有众所周知的抗氧化和抗炎特性。虽然它对健康个体的益处以及作为特级初榨橄榄油的一部分已经得到了很好的研究，但它作为一种膳食补充剂在高危人群中的预防作用仍未得到充分探讨。本研究探讨了HT补充剂在糖尿病前期超重个体中预防衰老相关疾病的潜力。方法采用随机、双盲、安慰剂对照的方法，对40 ~ 70岁的超重成人糖尿病前期患者进行研究。在16周的时间里，志愿者每天服用15毫克羟色胺或安慰剂。主要终点是氧化LDL （oxLDL）水平，次要终点包括生化和代谢参数、氧化应激和炎症生物标志物以及生活方式评估。通过尿HT-3 ' -硫酸盐水平验证依从性。结果共招募并随机选取52名参与者，其中49人完成了研究。然后他们被分配到ht治疗组（n = 24）或安慰剂组（n = 25）。证实了依从性，因为ht补充组显示尿HT-3 ' -硫酸盐水平升高，而安慰剂组显示显着降低（p = 0.039）。与安慰剂相比，HT补充剂显著降低了oxLDL水平（p = 0.045）、蛋白质羰基（p = 0.031）和8-OHdG (p <；0.01)。此外，它还能防止总抗氧化状态的下降(p <；0.01)和GPx活性(p <；0.01)。抗炎作用也被观察到，降低IL-6水平（p = 0.05）。在血脂、人体测量参数或生活方式因素（如睡眠、心理健康或身体能力）方面未发现显著变化。在整个干预过程中未观察到不良事件。结论慢性补充15 mg/d HT，持续16周，可显著改善超重和糖尿病前期患者的抗氧化和抗炎能力，提示其对衰老相关疾病有潜在的预防作用。临床试验注册号nct 06295913 （https://clinicaltrials.gov/study/NCT06295913?intr=Hydroxytyrosol&page=2&rank=1）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical nutrition 医学-营养学

CiteScore

14.10

自引率

6.30%

发文量

356

审稿时长

28 days

期刊介绍： Clinical Nutrition, the official journal of ESPEN, The European Society for Clinical Nutrition and Metabolism, is an international journal providing essential scientific information on nutritional and metabolic care and the relationship between nutrition and disease both in the setting of basic science and clinical practice. Published bi-monthly, each issue combines original articles and reviews providing an invaluable reference for any specialist concerned with these fields.